lexatumumab
mAbexperimental
Lexatumumab is an experimental agonistic human monoclonal antibody against TRAIL-R2, intended for the treatment of cancer. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 4, 2006 (NCT00428272)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF10B agonist
TNFRSF10B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLexatumumab ↗
- ChEMBLCHEMBL1743036 ↗
Also known as
- etr2-st01
- hgs1018
- hgs-etr2
- hgs-etr2
- lexatumumab
- lexatumumab
- lexatumumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00428272 | Phase 1 | Dec 4, 2006 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1